Milk-derived phospholipid supplement for adults with mild cognitive impairment
Tests a dairy milk extract supplement for thinking skills and safety in mild cognitive impairment.
Key facts
- Who runs it
- Pusan National University Yangsan Hospital
- Where
- South Korea1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Phospholipid-rich Dairy Extract for Cognitive Function
- Status
- Recruiting
- People taking part
- 100 people, planned
- Started
- 7 Jan 2025
- Expected to end
- 31 Dec 2026
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Phospholipid-rich dairy milk extract
- Placebo
- Record updated
- 12 June 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 55 to 85 with mild memory problems but no dementia. It tests whether a dairy milk extract rich in phospholipids (a type of fat) improves thinking and memory.
- Age
- 55 to 85 years
- Sex
- All sexes
- Disease stage
- Mild cognitive impairment: Global Deterioration Scale (GDS) score of 2-3. This means memory complaints without test evidence, or mild memory problems shown on tests. No dementia.
- Earlier treatment
- Cannot join if, in the past month, you used drugs or health functional foods that may affect thinking, such as antipsychotics, cognitive enhancers, tricyclic antidepressants or hormone replacement therapy.
Main reasons for not taking part
- Dementia, Parkinson's disease, cerebral infarction (stroke) or other conditions linked to memory decline
- Severe stroke, heart disease or cancer in the past 6 months (stable heart or stroke history may be allowed)
- Uncontrolled blood pressure (≥160/100 mmHg) or fasting blood glucose ≥160 mg/dL (8.9 mmol/L) in people with diabetes
- Kidney or liver problems: serum creatinine, AST or ALT ≥2 times the upper limit of normal
- Alcohol abuse, allergy to the study product, or another drug trial in the past month; must be able to read Korean
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- Age: Adults aged 55-85 years (inclusive), both male and female
- Global Deterioration Scale (GDS) score of 2-3:; GDS 2: Subjective memory impairment without objective evidence GDS 3: Mild objective memory impairment
- Absence of dementia according to established diagnostic criteria
- Ability to read Korean
Who cannot take part
- Uncontrolled thyroid dysfunction: Currently receiving treatment for uncontrolled hypothyroidism or hyperthyroidism
- Other clinical trial participation: Participation in other drug clinical trials within the past month or planned participation during the study period
- Severe medical conditions within the past 6 months: History of severe cerebrovascular disease (cerebral infarction, cerebral hemorrhage), cardiac disease (angina, myocardial infarction, heart failure, arrhythmia requiring treatment), or malignancy (Note: Participants with a history of cerebrovascular or cardiac disease who are clinically stable may be included at the investigator's discretion)
- Cognitive impairment-associated diseases: Dementia, Parkinson's disease, cerebral infarction, or other conditions associated with cognitive decline Uncontrolled hypertension: Blood pressure ≥160/100 mmHg (measured after 10 minutes of rest)
- Medications affecting cognitive function within the past month: Use of drugs (antipsychotics, anti-degenerative agents, cognitive enhancers, tricyclic antidepressants, hormone replacement therapy) or health functional foods that may influence cognitive function due to dementia or other cognitive abnormalities
- Food allergies: Known allergic reactions to study product components
- Investigator discretion: Any other condition deemed inappropriate for study participation by the investigator
- Poor glycemic control: Fasting blood glucose ≥160 mg/dL in diabetic patients
- Renal impairment: Serum creatinine ≥2 times the upper limit of normal for the institution
- Hepatic impairment: AST or ALT ≥2 times the upper limit of normal for the institution
- Severe gastrointestinal symptoms: Complaints of severe heartburn, dyspepsia, or other gastrointestinal distress
- Alcohol abuse
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 55 and 85 years old?
This trial is currently available in South Korea.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This clinical trial aims to determine whether dietary phospholipid-rich dairy milk extract improves cognitive function in adults with mild cognitive impairment and to assess its safety.
Read full original descriptionShow less
The main questions are:
* Does dietary phospholipid-rich dairy milk extract improve cognitive function in participants? * What side effects occur when participants take phospholipid-rich dairy milk extract?
The 2 groups in the trial
- Milk groupTreatment being tested
This group takes dietary phospholipid-rich dairy milk extract for 12 weeks.
Treatment: Phospholipid-rich dairy milk extract
- Placebo groupPlacebo, for comparison
This group takes placebo for 12 weeks.
Treatment: Placebo
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A 12-week Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of Dietary Phospholipid-rich Dairy Milk Extract on Cognitive Function Improvement in Adults With Mild Cognitive Impairment.
- Plain-language title
- Milk-derived phospholipid supplement for adults with mild cognitive impairmentGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Criteria questions
- Built from NCT07011680, who can take part
- Record updated
- 12 June 2025